Matinas Biopharma Holdings Inc (AMEX: MTNB) has seen a decline in its stock price by -0.38 in relation to its previous close of 0.16. However, the company has experienced a 3.51% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-06-24 that BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful treatment of a 22-year-old male with polymicrobial necrotizing fasciitis (flesh-eating disease) that involved drug-resistant Lichtheimia, an angio-invasive species of the fungus Mucorales. This patient was treated at New York Presbyterian/Weill Cornell Medical Center and was discharged after just six weeks of treatment with MAT2203, Matinas’ oral formulation of the potent antifungal amphotericin B. The patient was treated under Matinas’ Compassionate/ Expanded Use Access Program by Sharan Yadav, MD, Infectious Disease Fellow.
Is It Worth Investing in Matinas Biopharma Holdings Inc (AMEX: MTNB) Right Now?
Additionally, the 36-month beta value for MTNB is 1.70. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MTNB is 244.48M and currently, short sellers hold a 0.86% ratio of that float. The average trading volume of MTNB on June 28, 2024 was 1.24M shares.
MTNB’s Market Performance
The stock of Matinas Biopharma Holdings Inc (MTNB) has seen a 3.51% increase in the past week, with a -2.45% drop in the past month, and a -41.22% fall in the past quarter. The volatility ratio for the week is 5.98%, and the volatility levels for the past 30 days are at 5.37% for MTNB. The simple moving average for the last 20 days is 0.66% for MTNB stock, with a simple moving average of -24.00% for the last 200 days.
Analysts’ Opinion of MTNB
Piper Sandler gave a rating of “Overweight” to MTNB, setting the target price at $3 in the report published on January 27th of the previous year.
MTNB Trading at -5.64% from the 50-Day Moving Average
After a stumble in the market that brought MTNB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.10% of loss for the given period.
Volatility was left at 5.37%, however, over the last 30 days, the volatility rate increased by 5.98%, as shares surge +0.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.94% lower at present.
During the last 5 trading sessions, MTNB rose by +4.48%, which changed the moving average for the period of 200-days by -2.00% in comparison to the 20-day moving average, which settled at $0.1583. In addition, Matinas Biopharma Holdings Inc saw -26.32% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MTNB
Current profitability levels for the company are sitting at:
- 21.97 for the present operating margin
- 1.87 for the gross margin
The net margin for Matinas Biopharma Holdings Inc stands at 21.22. The total capital return value is set at -1.37. Equity return is now at value -98.57, with -80.36 for asset returns.
Based on Matinas Biopharma Holdings Inc (MTNB), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -4.99. The debt to equity ratio resting at 0.23. The interest coverage ratio of the stock is -329.89.
Currently, EBITDA for the company is -22.82 million with net debt to EBITDA at -0.1. When we switch over and look at the enterprise to sales, we see a ratio of -38.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.15.
Conclusion
In conclusion, Matinas Biopharma Holdings Inc (MTNB) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
